Zaditen SRO permits once-daily dosing with superior efficacy in the prophylaxis of asthma.
This international, multicenter clinical trial was designed to compare the efficacy and safety of two different formulations of ketotifen: Zaditen SRO and Zaditen Standard Form. In a randomized double-blind study over a 12-week treatment period, 3 parallel groups of asthmatic subjects received Zaditen SRO (2 mg once daily), Zaditen SRO (4 mg once daily), or Zaditen Standard Form (1 mg twice daily). Asthmatic subjects (362 evaluable cases, aged 6-29 years) kept daily records of clinical symptoms, use of concomitant medication, and peak flow recordings and were examined at 2-week intervals up to the end of the study. Zaditen SRO 4 mg administered once a day at night showed a statistically significant faster onset of action and was more clinically effective than Zaditen Standard Form. The Zaditen SRO 4-mg and 2-mg formulations were at least as well tolerated as the standard form, with somnolence occurring equally after both formulations. In conclusion, Zaditen SRO (4 mg once daily) was found to be equally safe and more effective in the prophylactic treatment of mild and moderate bronchial asthma than Zaditen Standard Form (1 mg twice daily).
Radielovic
P
P
Clinical Research Department, Sandoz Pharma Ltd., Basel, Switzerland.
Morley
J
J
Hansel
T T
TT
Medici
T C
TC
D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000503:physiopathology / Q000517:prevention & control*; D002648:Child; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007665:Ketotifen / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D012129:Respiratory Function Tests; D016896:Treatment Outcome
D003692:Delayed-Action Preparations; D007665:Ketotifen